Recent quarterly reports show Pfizer and Merck diverging in strategy, with Pfizer focusing on dividend defense and Merck prioritizing pipeline expansion. While Pfizer manages a steep decline in COVID-related revenue, Merck is absorbing multi-billion dollar acquisition charges to prepare for future p
